We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.75 | -3.52% | 48.00 | 47.50 | 48.50 | 49.75 | 47.75 | 49.75 | 3,004,767 | 14:40:26 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 10.06M | -39.19M | -0.1382 | -3.47 | 136.13M |
From Apr 2019 to Apr 2024
TIDMAVCT
RNS Number : 2759C
Avacta Group PLC
18 January 2018
18 January 2018
Avacta Group plc
("Avacta", "the Group" or "the Company")
Result of Annual General Meeting
Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.
The full text of each resolution is set out in the Notice of Annual General Meeting, included in the 2017 Annual Report, which is available on the Company's website www.avacta.com.
- Ends -
For further information from Avacta Group plc, please contact:
Hot Features
Premium
Avacta Group plc Tel: +44 (0)
Alastair Smith, Chief Executive 844 414 0452
Officer www.avacta.com
Tony Gardiner, Chief Financial
Officer
finnCap Ltd Tel: +44 (0)
Geoff Nash / Giles Rolls - Nominated 207 220 0500
Adviser www.finncap.com
Tim Redfern / Alice Lane / Nikita
Jain - Corporate Broking
WG Partners Tel: +44 (0)
Nigel Birks / Nigel Barnes 203 705 9318
David Wilson / Claes Spang Tel: +44 (0)
203 705 9217
www.wgpartners.co.uk
Zyme Communications (Trade and Tel: +44 (0)7787
Regional Media) 502 947
Katie Odgaard katie.odgaard@zymecommunications.com
Yellow Jersey PR (Financial Media Tel: +44 (0)7764
and IR) 947137
Sarah Hollins avacta@yellowjerseypr.com
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGGGUCPGUPRGGR
(END) Dow Jones Newswires
January 18, 2018 06:26 ET (11:26 GMT)
1 Year Avacta Chart |
1 Month Avacta Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
